| Literature DB >> 25961739 |
Jiangping Wen1, Jingang Yang2, Yujie Shi3, Yuanbo Liang4, Fenghua Wang5, Xinrong Duan5, Xilin Lu6, Qiushan Tao7, Xinxin Lu8, Yaping Tian9, Ningli Wang5.
Abstract
OBJECTIVES: We estimated the prevalence of metabolic syndrome (MetS) and compared associations of different MetS definitions with coronary heart disease (CHD), stroke, and peripheral arterial disease (PAD) in a rural Chinese population.Entities:
Mesh:
Year: 2015 PMID: 25961739 PMCID: PMC4427409 DOI: 10.1371/journal.pone.0126832
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of recruitment of participants in the analysis.
Definitions of the metabolic syndrome.
| Modified WHO [ | updated NCEP-ATPIII for Asian-Americans [ | IDF [ | JIS [ | CDS [ | |
|---|---|---|---|---|---|
|
| FPG ≥6.1 mmol/L or known treatment for diabetes | Ethnic-based WC ≥90 cm in men and ≥80 cm in women for Chinese | |||
|
| And ≥2 of: | ≥3 of: | And ≥2 of: | ≥3 of: | ≥3 of: |
|
| HDL-C <0.90 mmol/L in men or <1.03 mmol/L in women | <1.03 mmol/L in men or 1.30 mmol/L in women | <1.03 mmol/L in men or 1.30 mmol/L in women | <1.03 mmol/L in men or 1.30 mmol/L in women | <0.90 mmol/L in men or <1.03 mmol/L in women |
| and/or | and/or | ||||
|
| ≥1.7 mmol/L | ≥1.7 mmol/L | ≥1.7 mmol/L | ≥1.7 mmol/L | ≥1.7 mmol/L |
|
| FPG ≥5.6 mmol/L or known treatment for diabetes | FPG ≥5.6 mmol/L or known treatment for diabetes | FPG ≥5.6 mmol/L or known treatment for diabetes | FPG ≥6.1 mmol/L or known treatment for diabetes | |
|
| WHR >0.90 in men (>0.85 in women) and/or BMI >30 kg/m2 | WC ≥90 cm in men or ≥80 cm in women | Ethnic-based WC ≥85 cm in men or ≥80 cm in women for Chinese | BMI >25 kg/m2 | |
|
| ≥140/90 mmHg or use of antihypertensive drugs | ≥130/85 mmHg or use of antihypertensive drugs | ≥130/85 mmHg or use of antihypertensive drugs | ≥130/85 mmHg or use of antihypertensive drugs | ≥140/90 mmHg or use of antihypertensive drugs |
|
| Urinary albumin creatinine ratio ≥30 mg/g |
WHO, World Health Organization; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JIS, Joint Interim Statement; WHR, waist/hip rate; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TGs, triglycerides; FPG, fasting plasma glucose; WC, waist circumference.
Baseline characteristics of participants.
| Total (n = 4748) | Men (n = 2145) | Women (n = 2603) |
| |
|---|---|---|---|---|
|
| 52±11 | 52±11 | 51±11 | 0.034 |
|
| 24.6±3.7 | 24.3±3.5 | 24.9±3.8 | <0.001 |
|
| 87.5±9.3 | 88.4±8.9 | 86.7±9.5 | <0.001 |
|
| 0.90±0.05 | 0.92±0.05 | 0.88±0.05 | <0.001 |
|
| 138.8±21.9 | 138.2±21.1 | 139.4±22.6 | 0.063 |
|
| 77.6±12.1 | 77.9±12.4 | 77.4±11.8 | 0.205 |
|
| 4.61±0.95 | 4.46±0.88 | 4.73±0.98 | <0.001 |
|
| 1.28±0.29 | 1.23±0.28 | 1.32±0.29 | <0.001 |
|
| 2.71±0.65 | 2.62±0.60 | 2.78±0.68 | <0.001 |
|
| 1.25 (0.89–1.82) | 1.20 (0.85–1.78) | 1.29 (0.93–1.84) | <0.001 |
|
| 5.52 (5.18–5.95) | 5.53 (5.18–5.94) | 5.52 (5.19–5.97) | 0.231 |
|
| 8.66 (4.07–19.40) | 7.60 (3.63–16.67) | 9.69 (4.46–21.51) | <0.001 |
|
| 0.87 (0.37–2.23) | 0.81 (0.36–2.18) | 0.91 (0.38–2.28) | 0.256 |
|
| <0.001 | |||
|
| 3267 (68.8) | 667 (31.1) | 2600 (99.9) | |
|
| 221 (4.7) | 220 (10.3) | 1 (0.04) | |
|
| 1260 (26.5) | 1258 (58.6) | 2 (0.1) | |
|
| 885 (18.6) | 867 (40.4) | 18 (0.7) | <0.001 |
|
| <0.001 | |||
|
| 659 (13.9) | 159 (7.4) | 500 (19.2) | |
|
| 2420 (51.0) | 920 (42.9) | 1500 (57.6) | |
|
| 1517 (32.0) | 951 (44.3) | 566 (21.7) | |
|
| 152 (3.2) | 115 (5.4) | 37 (1.4) | |
|
| <0.001 | |||
|
| 903 (19.0) | 315 (14.7) | 588 (22.6) | |
|
| 3410 (71.8) | 1601 (74.6) | 1809 (69.5) | |
|
| 435 (9.2) | 229 (10.7) | 206 (7.9) | |
|
| 2295 (48.3) | 970 (45.2) | 1325 (50.9) | <0.001 |
|
| 305 (6.4) | 107 (5.0) | 198 (7.6) | <0.001 |
|
| 189 (4.0) | 78 (3.6) | 111 (4.3) | 0.271 |
|
| 113 (2.4) | 65 (3.0) | 48 (1.8) | 0.008 |
|
| 212 (4.5) | 74 (3.4) | 138 (5.3) | 0.002 |
|
| 916 (19.3) | 320 (14.9) | 596 (22.9) | <0.001 |
|
| 86 (1.8) | 42 (2.0) | 44 (1.7) | 0.491 |
|
| 318 (6.7) | 124 (5.8) | 194 (7.5) | 0.022 |
Data are presented as mean±SD, median (interquartile range) or percent. Chi-square test for categorical variables, the unpaired t test or Mann-Whitney U test for continuous variables.
aData on hsCRP was available for 1887 men and 2286 women.
BMI, body mass index; WHR, waist/hip rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; CHD, coronary heart disease; PAD, peripheral arterial disease.
Prevalence (%) of the metabolic syndrome of different definitions of and their individual components in Chinese men and women.
| Total (n = 4748) Prevalence (95% CI) | Men (n = 2145) Prevalence (95% CI) | Women (n = 2603) Prevalence (95% CI) |
| |
|---|---|---|---|---|
|
| ||||
|
| 13.8 (12.8–14.8) | 11.5 (10.2–12.9) | 15.7 (14.3–17.1) | <0.001 |
|
| 18.1 (17.0–19.1) | 14.8 (13.3–16.3) | 20.7 (19.2–22.3) | <0.001 |
|
| 44.3 (42.9–45.8) | 32.4 (30.4–34.3) | 54.2 (52.3–56.1) | <0.001 |
|
| 40.7 (39.3–42.1) | 27.5 (25.6–29.4) | 51.5 (49.6–53.4) | <0.001 |
|
| 47.7 (46.2–49.1) | 39.7 (37.7–41.8) | 54.2 (52.3–56.1) | <0.001 |
|
| ||||
|
| 48.3 (46.9–49.8) | 45.2 (43.1–47.3) | 50.9 (49.0–52.8) | <0.001 |
|
| 64.2 (62.9–65.6) | 63.2 (61.2–65.3) | 65.1 (63.3–66.9) | 0.183 |
|
| ||||
|
| 33.7 (32.4–35.1) | 31.9 (30.0–33.9) | 35.2 (33.4–37.0) | 0.018 |
|
| 29.3 (28.0–30.6) | 28.1 (26.2–30.0) | 30.4 (28.6–32.1) | 0.092 |
|
| 35.8 (34.4–37.1) | 18.3 (16.6–19.9) | 50.2 (48.3–52.1) | <0.001 |
|
| ||||
|
| 19.7 (18.6–20.9) | 18.4 (16.8–20.1) | 20.8 (19.2–22.3) | 0.041 |
|
| 45.2 (43.8–46.7) | 45.2 (43.1–47.3) | 45.3 (43.4–47.2) | 0.935 |
|
| ||||
|
| 73.1 (71.8–74.3) | 68.1 (66.1–70.1) | 77.1 (75.5–78.8) | <0.001 |
|
| 40.9 (39.5–42.3) | 36.3 (34.3–38.4) | 44.8 (42.8–46.7) | <0.001 |
|
| 60.9 (59.5–62.2) | 43.0 (40.9–45.1) | 75.5 (73.9–77.2) | <0.001 |
|
| 70.2 (68.9–71.5) | 63.7 (61.7–65.8) | 75.5 (73.9–77.2) | <0.001 |
|
| 16.3 (15.3–17.4) | 14.0 (12.6–15.5) | 18.2 (16.7–19.7) | <0.001 |
WHO, World Health Organization; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JIS, Joint Interim Statement; WHR, waist/hip rate; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TGs, triglycerides; FPG, fasting plasma glucose.
Fig 2Distribution of participants according to the number of definitions of metabolic syndrome.
Associations of the metabolic syndrome of different definitions and their individual components with cardiovascular disease in Chinese men.
| CHD (n = 78) Odds ratios (95% CI) | Stroke (n = 65) Odds ratios (95% CI) | PAD (n = 74) Odds ratios (95% CI) | CHD or Stroke or PAD (n = 201) Odds ratios (95% CI) | |
|---|---|---|---|---|
|
| ||||
|
| 1.79 (1.02–3.17) | 2.18 (1.20–3.97) | 2.25 (1.27–3.99) | 2.18 (1.50–3.17) |
|
| 1.25 (0.69–2.26) | 2.20 (1.25–3.89) | 2.09 (1.21–3.62) | 1.82 (1.26–2.62) |
|
| 1.61 (1.01–2.58) | 1.71 (1.02–2.84) | 1.92 (1.20–3.09) | 1.68 (1.24–2.28) |
|
| 1.84 (1.14–2.96) | 1.30 (0.77–2.23) | 1.85 (1.14–3.00) | 1.68 (1.23–2.30) |
|
| 1.53 (0.96–2.43) | 1.61 (0.97–2.68) | 2.26 (1.40–3.66) | 1.73 (1.28–2.34) |
|
| ||||
|
| 1.06 (0.65–1.73) | 2.21 (1.24–3.94) | 1.15 (0.70–1.90) | 1.27 (0.93–1.74) |
|
| 0.93 (0.55–1.58) | 1.95 (0.98–3.87) | 1.29 (0.75–2.22) | 1.22 (0.86–1.73) |
|
| ||||
|
| 0.90 (0.53–1.53) | 2.04 (1.21–3.43) | 1.56 (0.96–2.54) | 1.37 (1.00–1.89) |
|
| 0.68 (0.37–1.23) | 2.11 (1.24–3.59) | 1.75 (1.06–2.87) | 1.34 (0.96–1.87) |
|
| 1.83 (1.08–3.12) | 2.26 (1.30–3.96) | 1.03 (0.56–1.88) | 1.62 (1.13–2.30) |
|
| ||||
|
| 1.35 (0.80–2.30) | 1.79 (1.03–3.10) | 1.61 (0.94–2.74) | 1.62 (1.15–2.27) |
|
| 1.07 (0.68–1.70) | 1.17 (0.71–1.94) | 1.83 (1.13–2.94) | 1.30 (0.97–1.75) |
|
| ||||
|
| 1.09 (0.65–1.82) | 1.10 (0.63–1.92) | 2.20 (1.20–4.06) | 1.41 (1.00–1.99) |
|
| 1.66 (1.04–2.65) | 1.75 (1.05–2.91) | 1.74 (1.08–2.79) | 1.72 (1.27–2.33) |
|
| 1.85 (1.15–2.97) | 1.24 (0.74–2.06) | 1.88 (1.16–3.03) | 1.69 (1.25–2.28) |
|
| 1.61 (0.94–2.76) | 1.16 (0.67–2.00) | 2.07 (1.18–3.65) | 1.63 (1.16–2.28) |
|
| 1.04 (0.55–1.97) | 0.83 (0.40–1.72) | 1.49 (0.83–2.68) | 1.02 (0.68–1.54) |
Adjusted for age, education, physical exercise, smoking, alcohol use, family history of coronary heart disease.
WHO, World Health Organization; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JIS, Joint Interim Statement; WHR, waist/hip rate; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TGs, triglycerides; FPG, fasting plasma glucose; CHD, coronary heart disease; PAD, peripheral arterial disease.
Associations of the metabolic syndrome of different definitions and their individual components and cardiovascular disease in Chinese women.
| CHD (n = 111) Odds ratios (95% CI) | Stroke (n = 48) Odds ratios (95% CI) | PAD (n = 138) Odds ratios (95% CI) | CHD or Stroke or PAD (n = 284) Odds ratios (95% CI) | |
|---|---|---|---|---|
|
| ||||
|
| 1.92 (1.25–2.96) | 2.48 (1.35–4.55) | 1.19 (0.74–1.91) | 1.63 (1.20–2.21) |
|
| 1.79 (1.18–2.69) | 2.66 (1.47–4.81) | 0.98 (0.63–1.53) | 1.48 (1.11–1.97) |
|
| 1.69 (1.08–2.64) | 2.51 (1.19–5.32) | 0.98 (0.68–1.41) | 1.28 (0.98–1.68) |
|
| 1.85 (1.19–2.88) | 2.49 (1.21–5.11) | 1.02 (0.71–1.47) | 1.36 (1.04–1.77) |
|
| 1.69 (1.08–2.64) | 2.51 (1.19–5.32) | 0.98 (0.68–1.41) | 1.28 (0.98–1.68) |
|
| ||||
|
| 1.23 (0.79–1.90) | 3.11 (1.40–6.93) | 0.53 (0.37–0.79) | 0.89 (0.68–1.17) |
|
| 1.12 (0.68–1.83) | 8.08 (1.91–34.22) | 0.59 (0.40–0.86) | 0.87 (0.65–1.16) |
|
| ||||
|
| 1.30 (0.87–1.92) | 1.31 (0.73–2.35) | 1.02 (0.71–1.46) | 1.17 (0.90–1.51) |
|
| 1.42 (0.95–2.11) | 1.40 (0.78–2.53) | 1.01 (0.69–1.48) | 1.21 (0.93–1.58) |
|
| 1.36 (0.92–2.01) | 1.32 (0.74–2.38) | 0.98 (0.70–1.39) | 1.15 (0.90–1.48) |
|
| ||||
|
| 1.46 (0.95–2.23) | 2.46 (1.36–4.43) | 1.33 (0.88–2.00) | 1.52 (1.15–2.02) |
|
| 1.39 (0.93–2.08) | 1.53 (0.84–2.80) | 1.49 (1.04–2.12) | 1.39 (1.08–1.80) |
|
| ||||
|
| 1.37 (0.79–2.38) | 1.86 (0.73–4.77) | 1.38 (0.88–2.17) | 1.40 (0.99–1.96) |
|
| 1.38 (0.93–2.04) | 1.26 (0.71–2.24) | 1.44 (1.02–2.04) | 1.35 (1.05–1.73) |
|
| 1.53 (0.87–2.69) | 2.07 (0.81–5.31) | 1.26 (0.82–1.94) | 1.35 (0.97–1.88) |
|
| 1.53 (0.87–2.69) | 2.07 (0.81–5.31) | 1.26 (0.82–1.94) | 1.35 (0.97–1.88) |
|
| 1.44 (0.93–2.25) | 0.70 (0.32–1.52) | 1.10 (0.71–1.72) | 1.16 (0.85–1.58) |
Adjusted for age, education, physical exercise, smoking, alcohol use, family history of coronary heart disease.
WHO, World Health Organization; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JIS, Joint Interim Statement; WHR, waist/hip rate; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TGs, triglycerides; FPG, fasting plasma glucose; CHD, coronary heart disease; PAD, peripheral arterial disease.